메뉴 건너뛰기




Volumn 95, Issue 3, 2015, Pages 272-281

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians

Author keywords

Bevacizumab; Colorectal cancer; Liver metastases; Neoadjuvant; Response criteria

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PERFLUBUTANE; FLUORODEOXYGLUCOSE F 18;

EID: 84938485242     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.04.008     Document Type: Review
Times cited : (14)

References (52)
  • 2
    • 0022969737 scopus 로고
    • Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies
    • Weiss L., Grundmann E., Torhorst J., Hartveit F., Moberg I., Eder M., et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986, 150:195-203.
    • (1986) J Pathol , vol.150 , pp. 195-203
    • Weiss, L.1    Grundmann, E.2    Torhorst, J.3    Hartveit, F.4    Moberg, I.5    Eder, M.6
  • 3
    • 66149155832 scopus 로고    scopus 로고
    • Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
    • Nordlinger B., Van Cutsem E., Gruenberger T., Glimelius B., Poston G., Rougier P., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992.
    • (2009) Ann Oncol , vol.20 , pp. 985-992
    • Nordlinger, B.1    Van Cutsem, E.2    Gruenberger, T.3    Glimelius, B.4    Poston, G.5    Rougier, P.6
  • 4
    • 36749073541 scopus 로고    scopus 로고
    • Bringing unresectable liver disease to resection with curative intent
    • Wicherts D.A., de Haas R.J., Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 2007, 33(Suppl. 2):S42-S51.
    • (2007) Eur J Surg Oncol , vol.33 , pp. S42-S51
    • Wicherts, D.A.1    de Haas, R.J.2    Adam, R.3
  • 5
    • 84887887741 scopus 로고    scopus 로고
    • Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
    • Rossi L., Vakiarou F., Zoratto F., Bianchi L., Papa A., Basso E., et al. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res 2013, 5:377-385.
    • (2013) Cancer Manag Res , vol.5 , pp. 377-385
    • Rossi, L.1    Vakiarou, F.2    Zoratto, F.3    Bianchi, L.4    Papa, A.5    Basso, E.6
  • 6
    • 79959947067 scopus 로고    scopus 로고
    • A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    • Wong R., Cunningham D., Barbachano Y., Saffery C., Valle J., Hickish T., et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011, 22:2042-2048.
    • (2011) Ann Oncol , vol.22 , pp. 2042-2048
    • Wong, R.1    Cunningham, D.2    Barbachano, Y.3    Saffery, C.4    Valle, J.5    Hickish, T.6
  • 7
    • 84894598632 scopus 로고    scopus 로고
    • Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA
    • (abstr 3619)
    • Gruenberger T., Bridgewater J.A., Chau I., Alfonso P.G., Rivoire M., Lasserre S., et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. J Clin Oncol 2013, 24. (Suppl, abstr 3619).
    • (2013) J Clin Oncol , vol.24 , Issue.SUPPL
    • Gruenberger, T.1    Bridgewater, J.A.2    Chau, I.3    Alfonso, P.G.4    Rivoire, M.5    Lasserre, S.6
  • 8
    • 84908153983 scopus 로고    scopus 로고
    • Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer
    • Varol U., Yildiz I., Salman T., Karabulut B., Uslu R. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014, 100(July-August (4)):370-376.
    • (2014) Tumori , vol.100 , Issue.4 JULY AUGUST , pp. 370-376
    • Varol, U.1    Yildiz, I.2    Salman, T.3    Karabulut, B.4    Uslu, R.5
  • 9
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3    Schwartz, L.H.4    Sargent, D.5    Ford, R.6
  • 10
    • 61549118453 scopus 로고    scopus 로고
    • Targeted therapies in lung cancer
    • Pirker R., Filipits M. Targeted therapies in lung cancer. Curr Pharm Des 2009, 15:188-206.
    • (2009) Curr Pharm Des , vol.15 , pp. 188-206
    • Pirker, R.1    Filipits, M.2
  • 11
    • 78049361913 scopus 로고    scopus 로고
    • Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer
    • Bertino E.M., Otterson G.A. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010, 70:233-246.
    • (2010) Lung Cancer , vol.70 , pp. 233-246
    • Bertino, E.M.1    Otterson, G.A.2
  • 12
    • 38349189743 scopus 로고    scopus 로고
    • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    • Grothey A., Hedrick E.E., Mass R.D., Sarkar S., Suzuki S., Ramanathan R.K., et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008, 26:183-189.
    • (2008) J Clin Oncol , vol.26 , pp. 183-189
    • Grothey, A.1    Hedrick, E.E.2    Mass, R.D.3    Sarkar, S.4    Suzuki, S.5    Ramanathan, R.K.6
  • 13
    • 79956107589 scopus 로고    scopus 로고
    • New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy
    • Lee H.Y., Lee K.S., Ahn M.-J., Hwang H.S., Lee J.W., Park K., et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 2011, 73:63-69.
    • (2011) Lung Cancer , vol.73 , pp. 63-69
    • Lee, H.Y.1    Lee, K.S.2    Ahn, M.-J.3    Hwang, H.S.4    Lee, J.W.5    Park, K.6
  • 14
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
    • (2004) J Clin Oncol , vol.22 , pp. 2184-2191
    • Johnson, D.H.1    Fehrenbacher, L.2    Novotny, W.F.3    Herbst, R.S.4    Nemunaitis, J.J.5    Jablons, D.M.6
  • 15
    • 63049122188 scopus 로고    scopus 로고
    • Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab
    • Sandler A.B., Schiller J.H., Gray R., Dimery I., Brahmer J., Samant M., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009, 27:1405-1412.
    • (2009) J Clin Oncol , vol.27 , pp. 1405-1412
    • Sandler, A.B.1    Schiller, J.H.2    Gray, R.3    Dimery, I.4    Brahmer, J.5    Samant, M.6
  • 16
    • 84866859311 scopus 로고    scopus 로고
    • Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria
    • Chung W.S., Park M.S., Shin S.J., Baek S.E., Kim Y.E., Choi J.Y., et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol 2012, 199:809-815.
    • (2012) AJR Am J Roentgenol , vol.199 , pp. 809-815
    • Chung, W.S.1    Park, M.S.2    Shin, S.J.3    Baek, S.E.4    Kim, Y.E.5    Choi, J.Y.6
  • 17
    • 72249083700 scopus 로고    scopus 로고
    • Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
    • Chun Y.S., Vauthey J.-N., Boonsirikamchai P., Maru D.M., Kopetz S., Palavecino M., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009, 302:2338-2344.
    • (2009) JAMA , vol.302 , pp. 2338-2344
    • Chun, Y.S.1    Vauthey, J.-N.2    Boonsirikamchai, P.3    Maru, D.M.4    Kopetz, S.5    Palavecino, M.6
  • 18
    • 84871802981 scopus 로고    scopus 로고
    • Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    • Shindoh J., Loyer E.M., Kopetz S., Boonsirikamchai P., Maru D.M., Chun Y.S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012, 30:4566-4572.
    • (2012) J Clin Oncol , vol.30 , pp. 4566-4572
    • Shindoh, J.1    Loyer, E.M.2    Kopetz, S.3    Boonsirikamchai, P.4    Maru, D.M.5    Chun, Y.S.6
  • 19
    • 34249085905 scopus 로고    scopus 로고
    • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria
    • Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
    • (2007) J Clin Oncol , vol.25 , pp. 1753-1759
    • Choi, H.1    Charnsangavej, C.2    Faria, S.C.3    Macapinlac, H.A.4    Burgess, M.A.5    Patel, S.R.6
  • 20
    • 56749096759 scopus 로고    scopus 로고
    • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    • Blazer D.G., Kishi Y., Maru D.M., Kopetz S., Chun Y.S., Overman M.J., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26:5344-5351.
    • (2008) J Clin Oncol , vol.26 , pp. 5344-5351
    • Blazer, D.G.1    Kishi, Y.2    Maru, D.M.3    Kopetz, S.4    Chun, Y.S.5    Overman, M.J.6
  • 21
    • 34250637909 scopus 로고    scopus 로고
    • The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings
    • Lubezky N., Metse U., Geva R., Nakache R., Shmeli E., Klausener J.M., et al. The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007, 11:472-478.
    • (2007) J Gastrointest Surg , vol.11 , pp. 472-478
    • Lubezky, N.1    Metse, U.2    Geva, R.3    Nakache, R.4    Shmeli, E.5    Klausener, J.M.6
  • 22
    • 35748963541 scopus 로고    scopus 로고
    • Current controversies in the surgical management of colorectal cancer metastases to the liver
    • Small R., Luberky N., Ben-Haim M. Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 2007, 9:742-747.
    • (2007) Isr Med Assoc J , vol.9 , pp. 742-747
    • Small, R.1    Luberky, N.2    Ben-Haim, M.3
  • 23
    • 29144504049 scopus 로고    scopus 로고
    • The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases
    • Wiering B., Krabbe P.F., Jager G.J., Oyen W.J., Ruers T.J. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005, 104:2658-2670.
    • (2005) Cancer , vol.104 , pp. 2658-2670
    • Wiering, B.1    Krabbe, P.F.2    Jager, G.J.3    Oyen, W.J.4    Ruers, T.J.5
  • 24
    • 4344615981 scopus 로고    scopus 로고
    • Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)
    • discussion 447-50
    • Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240:438-447. discussion 447-50.
    • (2004) Ann Surg , vol.240 , pp. 438-447
    • Fernandez, F.G.1    Drebin, J.A.2    Linehan, D.C.3    Dehdashti, F.4    Siegel, B.A.5    Strasberg, S.M.6
  • 25
    • 15944429402 scopus 로고    scopus 로고
    • Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases
    • Truant S., Huglo D., Hebbar M., Ernst O., Steinling M., Pruvot F.R. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005, 92:362-369.
    • (2005) Br J Surg , vol.92 , pp. 362-369
    • Truant, S.1    Huglo, D.2    Hebbar, M.3    Ernst, O.4    Steinling, M.5    Pruvot, F.R.6
  • 26
    • 84877049819 scopus 로고    scopus 로고
    • Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial
    • Nasti G., Piccirillo M.C., Izzo F., Ottaiano A., Albino V., Delrio P., et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer 2013, 108:1566-1570.
    • (2013) Br J Cancer , vol.108 , pp. 1566-1570
    • Nasti, G.1    Piccirillo, M.C.2    Izzo, F.3    Ottaiano, A.4    Albino, V.5    Delrio, P.6
  • 27
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
    • (2004) Nat Med , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    di Tomaso, E.3    Duda, D.G.4    Munn, L.L.5    Tong, R.T.6
  • 28
    • 84055167359 scopus 로고    scopus 로고
    • Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)
    • Jiang T., Kambadakone A., Kulkarni N.M., Zhu A.X., Sahani D.V. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012, 47:11-17.
    • (2012) Invest Radiol , vol.47 , pp. 11-17
    • Jiang, T.1    Kambadakone, A.2    Kulkarni, N.M.3    Zhu, A.X.4    Sahani, D.V.5
  • 29
    • 0347615101 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
    • Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955-3964.
    • (2003) J Clin Oncol , vol.21 , pp. 3955-3964
    • Morgan, B.1    Thomas, A.L.2    Drevs, J.3    Hennig, J.4    Buchert, M.5    Jivan, A.6
  • 30
    • 83755180887 scopus 로고    scopus 로고
    • Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis
    • Hirashima Y., Yamada Y., Tateishi U., Kato K., Miyake M., Horita Y., et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012, 130:2359-2365.
    • (2012) Int J Cancer , vol.130 , pp. 2359-2365
    • Hirashima, Y.1    Yamada, Y.2    Tateishi, U.3    Kato, K.4    Miyake, M.5    Horita, Y.6
  • 31
    • 53749092242 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
    • Hahn O.M., Yang C., Medved M., Karczmar G., Kistner E., Karrison T., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
    • (2008) J Clin Oncol , vol.26 , pp. 4572-4578
    • Hahn, O.M.1    Yang, C.2    Medved, M.3    Karczmar, G.4    Kistner, E.5    Karrison, T.6
  • 32
    • 84879793148 scopus 로고    scopus 로고
    • Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography
    • Osawa G., Yoshimatsu K., Yokomizo H., Okayama S., Sagawa M., Naritaka Y. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. Cancer Chemother Pharmacol 2013, 72:209-215.
    • (2013) Cancer Chemother Pharmacol , vol.72 , pp. 209-215
    • Osawa, G.1    Yoshimatsu, K.2    Yokomizo, H.3    Okayama, S.4    Sagawa, M.5    Naritaka, Y.6
  • 34
    • 84903310621 scopus 로고    scopus 로고
    • Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy
    • Arita J1, Ono Y., Takahashi M., Inoue Y., Takahashi Y., Saiura A. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol 2014, 21(Suppl. 3):S390-S397.
    • (2014) Ann Surg Oncol , vol.21 , pp. S390-S397
    • Arita, J.1.1    Ono, Y.2    Takahashi, M.3    Inoue, Y.4    Takahashi, Y.5    Saiura, A.6
  • 35
    • 84858124994 scopus 로고    scopus 로고
    • Dual-energy CT with single- and dual-source scanners: current applications in evaluating the genitourinary tract
    • Kaza R.K., Platt J.F., Cohan R.H., Caoili E.M., Al-Hawary M.M., Wasnik A. Dual-energy CT with single- and dual-source scanners: current applications in evaluating the genitourinary tract. Radiographics 2012, 32:353-369.
    • (2012) Radiographics , vol.32 , pp. 353-369
    • Kaza, R.K.1    Platt, J.F.2    Cohan, R.H.3    Caoili, E.M.4    Al-Hawary, M.M.5    Wasnik, A.6
  • 36
    • 84868327045 scopus 로고    scopus 로고
    • Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
    • Kim Y.N., Lee H.Y., Lee K.S., Seo J.B., Chung M.J., Ahn M.J., et al. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?. Korean J Radiol 2012, 13:702-710.
    • (2012) Korean J Radiol , vol.13 , pp. 702-710
    • Kim, Y.N.1    Lee, H.Y.2    Lee, K.S.3    Seo, J.B.4    Chung, M.J.5    Ahn, M.J.6
  • 38
    • 24644486057 scopus 로고    scopus 로고
    • Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy
    • Schott A.F., Roubidoux M.A., Helvie M.A., Hayes D.F., Kleer C.G., Newman L.A., et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005, 92:231-238.
    • (2005) Breast Cancer Res Treat , vol.92 , pp. 231-238
    • Schott, A.F.1    Roubidoux, M.A.2    Helvie, M.A.3    Hayes, D.F.4    Kleer, C.G.5    Newman, L.A.6
  • 39
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
    • (1999) J Clin Oncol , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.L.3    Ames, F.C.4    Hunt, K.K.5    Dhingra, K.6
  • 40
    • 0028305674 scopus 로고
    • Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
    • Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.F., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73:2680-2686.
    • (1994) Cancer , vol.73 , pp. 2680-2686
    • Mandard, A.M.1    Dalibard, F.2    Mandard, J.C.3    Marnay, J.4    Henry-Amar, M.5    Petiot, J.F.6
  • 41
    • 20044366529 scopus 로고    scopus 로고
    • Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome
    • Ajani J.A., Mansfield P.F., Crane C.H., Wu T.T., Lunagomez S., Lynch P.M., et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005, 23:1237-1244.
    • (2005) J Clin Oncol , vol.23 , pp. 1237-1244
    • Ajani, J.A.1    Mansfield, P.F.2    Crane, C.H.3    Wu, T.T.4    Lunagomez, S.5    Lynch, P.M.6
  • 42
    • 33644842988 scopus 로고    scopus 로고
    • Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer
    • Rödel C., Martus P., Papadoupolos T., Füzesi L., Klimpfinger M., Fietkau R., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
    • (2005) J Clin Oncol , vol.23 , pp. 8688-8696
    • Rödel, C.1    Martus, P.2    Papadoupolos, T.3    Füzesi, L.4    Klimpfinger, M.5    Fietkau, R.6
  • 43
    • 33847333193 scopus 로고    scopus 로고
    • Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
    • Rubbia-Brandt L., Giostra E., Brezault C., Roth A.D., Andres A., Audard V., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18:299-304.
    • (2007) Ann Oncol , vol.18 , pp. 299-304
    • Rubbia-Brandt, L.1    Giostra, E.2    Brezault, C.3    Roth, A.D.4    Andres, A.5    Audard, V.6
  • 44
    • 78049457753 scopus 로고    scopus 로고
    • Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases
    • Kishi Y., Zorzi D., Contreras C.M., Maru D.M., Kopetz S., Ribero D., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010, 17:2870-2876.
    • (2010) Ann Surg Oncol , vol.17 , pp. 2870-2876
    • Kishi, Y.1    Zorzi, D.2    Contreras, C.M.3    Maru, D.M.4    Kopetz, S.5    Ribero, D.6
  • 45
    • 77954954904 scopus 로고    scopus 로고
    • Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX
    • Klinger M., Tamandl D., Eipeldauer S., Hacker S., Herberger B., Kaczirek K., et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010, 17:2059-2065.
    • (2010) Ann Surg Oncol , vol.17 , pp. 2059-2065
    • Klinger, M.1    Tamandl, D.2    Eipeldauer, S.3    Hacker, S.4    Herberger, B.5    Kaczirek, K.6
  • 46
    • 84879690214 scopus 로고    scopus 로고
    • Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    • Loupakis F., Schirripa M., Caparello C., Funel N., Pollina L., Vasile E., et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013, 108:2549-2556.
    • (2013) Br J Cancer , vol.108 , pp. 2549-2556
    • Loupakis, F.1    Schirripa, M.2    Caparello, C.3    Funel, N.4    Pollina, L.5    Vasile, E.6
  • 47
    • 84867881665 scopus 로고    scopus 로고
    • Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
    • Gruenberger T., Arnold D., Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 2012, 21:309-315.
    • (2012) Surg Oncol , vol.21 , pp. 309-315
    • Gruenberger, T.1    Arnold, D.2    Rubbia-Brandt, L.3
  • 48
    • 84859110959 scopus 로고    scopus 로고
    • Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy
    • Chang H.H.L., Leeper W.R., Chan G., Quan D., Driman D.K. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012, 36:570-576.
    • (2012) Am J Surg Pathol , vol.36 , pp. 570-576
    • Chang, H.H.L.1    Leeper, W.R.2    Chan, G.3    Quan, D.4    Driman, D.K.5
  • 49
    • 84890442385 scopus 로고    scopus 로고
    • Comment on "Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab"
    • Bibeau F., Gil H., Castan F., Boissière-Michot F. Comment on "Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab". Br J Cancer 2013, 109:3127-3129.
    • (2013) Br J Cancer , vol.109 , pp. 3127-3129
    • Bibeau, F.1    Gil, H.2    Castan, F.3    Boissière-Michot, F.4
  • 50
    • 77956225027 scopus 로고    scopus 로고
    • Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    • Maru D.M., Kopetz S., Boonsirikamchai P., Agarwal A., Chun Y.S., Wang H., et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010, 34:1287-1294.
    • (2010) Am J Surg Pathol , vol.34 , pp. 1287-1294
    • Maru, D.M.1    Kopetz, S.2    Boonsirikamchai, P.3    Agarwal, A.4    Chun, Y.S.5    Wang, H.6
  • 51
    • 84930805289 scopus 로고    scopus 로고
    • Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?
    • Dede K., Salamon F., Landherr L., Jakab F., Bursics A. Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?. Pathol Oncol Res 2015, 21:173-179.
    • (2015) Pathol Oncol Res , vol.21 , pp. 173-179
    • Dede, K.1    Salamon, F.2    Landherr, L.3    Jakab, F.4    Bursics, A.5
  • 52
    • 37048998995 scopus 로고    scopus 로고
    • Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    • Ribero D., Wang H., Donadon M., Zorzi D., Thomas M.B., Eng C., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110:2761-2767.
    • (2007) Cancer , vol.110 , pp. 2761-2767
    • Ribero, D.1    Wang, H.2    Donadon, M.3    Zorzi, D.4    Thomas, M.B.5    Eng, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.